Fisher MJ, Shih C-S, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, Zhang C, Angus SP, Johnson GL, Packer RJ, Allen JC, Ullrich NJ, Goldman S, Gutmann DH, Plotkin SR, Rosser T, Robertson KA, Widemann BC, Smith AE, Bessler WK, He Y, Park S-J, Mund JA, Jiang L, Bijangi-Vishehsaraei K, Thomas C, Cutter GR, Korf B, Blakeley JO, Clapp DW. Kinase enrichment proteomics inform mechanism of action and biomarker discovery in a Neurofibromatosis Clinical Trials Consortium phase 2 clinical trial of cabozantinib (XL184) for neurofibromatosis type 1 related plexiform neurofibromas Nature Medicine.